Mineralys Reported Positive Trial Results for Lorundrostat
New clinical trial data show the drug effectively reduced blood pressure in patients with hypertension and sleep apnea.
Updated on Oct. 10, 2026 in Sleep Disorders
Live Poll
Do you believe pharmaceutical innovation is the most effective approach for managing chronic health conditions?
Mineralys Therapeutics has released new trial results indicating that its drug, lorundrostat, successfully reduced systolic blood pressure. The findings stem from the Launch-HTN and Explore-OSA trials, which targeted patients with uncontrolled or treatment-resistant hypertension.
Why it matters
These results provide a potential new intervention for managing high blood pressure and related conditions like obstructive sleep apnea. By targeting dysregulated aldosterone levels, the drug aims to address the significant health and economic burdens posed by treatment-resistant hypertension.
In the Launch-HTN trial, 46% of patients on 50 mg of lorundrostat reached a systolic blood pressure target below 130 mmHg. Additionally, the Explore-OSA trial demonstrated a 11.1 mmHg reduction in morning systolic blood pressure at four weeks.
The players
Mineralys Therapeutics
Based in Radnor, Pennsylvania, this clinical-stage biopharmaceutical company focuses on developing therapies for diseases driven by dysregulated aldosterone.
The details
The Launch-HTN study focused on patients with treatment-resistant hypertension using automated office monitoring, while the Explore-OSA study monitored participants during overnight polysomnography. Although the drug showed significant blood pressure improvements, researchers noted no measurable change in apnea-hypopnea indices during the sleep apnea trial.
Timeline
2019: Annual economic burden of hypertension in the United States was estimated at $219 billion.
2022: Hypertension was involved in 685,000 deaths across the United States.
Week 4: Morning systolic blood pressure reduction was measured in the Explore-OSA trial.
Week 12: Measurement point for systolic blood pressure in the Launch-HTN trial.
The Big Picture
The clinical trials of lorundrostat mark a shift in how pharmaceutical companies address aldosterone-driven hypertension compared to traditional standards. This research follows the broader industry pattern of developing highly targeted therapies for treatment-resistant patient populations.
These findings suggest that patients struggling with resistant hypertension or sleep apnea may have a new potential treatment option in the future. Consult with your healthcare provider to discuss how evolving blood pressure management therapies might fit into your existing health routine.
The takeaway
Management of resistant hypertension remains a critical health challenge for millions of Americans. Discussing your blood pressure goals with a specialist can help ensure you are aware of both established and emerging therapeutic options.
Further reading
For additional context on modern management strategies, visit the Sleep Disorders section.
More information
To review the full company documentation, visit the Mineralys Therapeutics corporate website.
Live Poll
Do you believe pharmaceutical innovation is the most effective approach for managing chronic health conditions?
